{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T13:44:35Z","timestamp":1776951875566,"version":"3.51.4"},"reference-count":15,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,9,16]],"date-time":"2008-09-16T00:00:00Z","timestamp":1221523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Basic Microbiol."],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dalbavancin is a new new semisynthetic teicoplanin\u2010related lipoglycopeptide with activity against gram\u2010positive organisms. We investigated the activity of dalbavancin against faecal enterococci isolates from wild animals, pets, poultry and healthy humans in Portugal.<\/jats:p><jats:p>The <jats:italic>in vitro <\/jats:italic> activity of dalbavancin was determined by the microbroth dilution method according to the Clinical Laboratory Standards Institute (CLSI) guidelines in 589 enterococci of different species and origins. All vancomycin\u2010susceptible <jats:italic>Enterococcus<\/jats:italic> spp. were inhibited by \u22640.25 mg\/l dalbavancin. Although vancomycin\u2010resistant\u2010enterococci (VRE) showed higher dalbavancin MIC values (16 mg\/l), the isolates that exhibited the VanC resistance phenotype were inhibited at dalbavancin concentrations \u22640.125 mg\/l. Only v<jats:italic>an<\/jats:italic> A isolates were not inhibited by low concentrations of dalbavancin since <jats:italic>van<\/jats:italic> A strains showed higher dalbavancin MIC values (16 mg\/l). (\u00a9 2008 WILEY\u2010VCH Verlag GmbH &amp; Co. KGaA, Weinheim)<\/jats:p>","DOI":"10.1002\/jobm.200800146","type":"journal-article","created":{"date-parts":[[2008,9,16]],"date-time":"2008-09-16T16:19:56Z","timestamp":1221581996000},"page":"526-528","source":"Crossref","is-referenced-by-count":4,"title":["<i>In vitro<\/i> activity of dalbavancin against enterococci isolates from wild animals, pets, poultry and humans in Portugal"],"prefix":"10.1002","volume":"48","author":[{"given":"Patricia","family":"Poeta","sequence":"first","affiliation":[]},{"given":"Hajer","family":"Radhouani","sequence":"additional","affiliation":[]},{"given":"Roberto","family":"Sargo","sequence":"additional","affiliation":[]},{"given":"Gilberto","family":"Igrejas","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2008,12,5]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.7.1580"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.suppl_1.1"},{"key":"e_1_2_1_4_2","unstructured":"Centers for Disease Control and Prevention 2002.Staphylococcus aureusresistant to vancomycin. Mor Mort Wkly Rep United States."},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.2.179"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2001.13.3.244"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.6.1968-1971.2003"},{"key":"e_1_2_1_8_2","first-page":"97","article-title":"A comparison of available and investigational antibiotics for complicated skin infections and treatment\u2010resistant Staphylococcus aureus and Enterococcus","volume":"6","author":"Scheinfeld N.","year":"2007","journal-title":"J. Drugs Dermatol."},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2005.17.6.593"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2003.09.004"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2006.06.003"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh549"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.09.018"},{"key":"e_1_2_1_14_2","unstructured":"Clinical and Laboratory Standards Institute 2007. Performance standards for antimicrobial susceptibility testing: seventeenth informational supplement. CLSI document M100\u2010S17 Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464090-00001"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.12.2.117"}],"container-title":["Journal of Basic Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjobm.200800146","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjobm.200800146","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jobm.200800146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T10:47:01Z","timestamp":1699958821000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jobm.200800146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["10.1002\/jobm.200800146"],"URL":"https:\/\/doi.org\/10.1002\/jobm.200800146","archive":["Portico"],"relation":{},"ISSN":["0233-111X","1521-4028"],"issn-type":[{"value":"0233-111X","type":"print"},{"value":"1521-4028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}